Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood
- PMID: 10217596
- DOI: 10.1016/s0264-410x(98)00458-7
Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood
Abstract
Avidity of antibodies to Streptococcus pneumoniae type 6B, 14, 19F and 23F polysaccharides (PS) evoked by four different pneumococcal conjugate vaccines was compared. Infants were primed with pneumococcal PS conjugated to the variant diphtheria toxin CRM197 (PncCRM), diphtheria toxoid (PncD), tetanus toxoid (PncT) or meningococcal protein complex (PncOMPC) and boosted with the homologous conjugate or PS vaccine. No booster was given to children in the PncOMPC group. Relative antibody avidity was measured by thiocyanate EIA. No vaccine specific differences were found in avidity of anti-14 or -19F antibodies. By contrast, antibody avidity to 6B and 23F differed significantly between the vaccine groups, PncCRM and PncT inducing antibodies of highest avidity.
Similar articles
-
Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.J Infect Dis. 1998 Jun;177(6):1614-21. doi: 10.1086/515298. J Infect Dis. 1998. PMID: 9607841
-
IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines.Vaccine. 1999 Apr 9;17(15-16):1889-97. doi: 10.1016/s0264-410x(98)00475-7. Vaccine. 1999. PMID: 10217586 Clinical Trial.
-
Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.J Infect Dis. 2001 Nov 1;184(9):1211-5. doi: 10.1086/323648. Epub 2001 Sep 25. J Infect Dis. 2001. PMID: 11598848 Clinical Trial.
-
Immunogenicity of pneumococcal conjugate vaccines.Pediatr Infect Dis J. 2000 Apr;19(4):388-93. doi: 10.1097/00006454-200004000-00035. Pediatr Infect Dis J. 2000. PMID: 10783041 Review.
-
Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.Vaccine. 2017 Feb 7;35(6):865-872. doi: 10.1016/j.vaccine.2016.12.055. Epub 2017 Jan 10. Vaccine. 2017. PMID: 28087148 Review.
Cited by
-
Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.Vaccine. 2011 Jun 15;29(27):4499-506. doi: 10.1016/j.vaccine.2011.04.038. Epub 2011 May 1. Vaccine. 2011. PMID: 21539882 Free PMC article. Clinical Trial.
-
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.Infect Immun. 2007 Apr;75(4):1794-800. doi: 10.1128/IAI.01673-06. Epub 2007 Jan 29. Infect Immun. 2007. PMID: 17261612 Free PMC article. Clinical Trial.
-
Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.Clin Vaccine Immunol. 2007 Apr;14(4):397-403. doi: 10.1128/CVI.00241-06. Epub 2007 Feb 7. Clin Vaccine Immunol. 2007. PMID: 17287312 Free PMC article.
-
Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination.Infect Immun. 1999 Sep;67(9):4935-8. doi: 10.1128/IAI.67.9.4935-4938.1999. Infect Immun. 1999. PMID: 10456954 Free PMC article.
-
Advances in pneumococcal vaccines: advantages for infants and children.Drugs. 2005;65(2):229-55. doi: 10.2165/00003495-200565020-00005. Drugs. 2005. PMID: 15631543 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources